About ArkeaBio
ArkeaBio is a private company based in Charlestown, Massachusetts. It has reported $21,999,994 raised in three offerings on Form D since December 2023. Its chief executive is Frank Wooten.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Oct 9, 2026 | $14,999,995of $32.9M target | 2 | $7.4M | EquityRule 506(b) | Form D ↗ |
| Sep 26, 2025 | Oct 14, 2025 | $6,999,999of $12.0M target | 2 | $3.4M | EquityRule 506(b) | Form D ↗ |
| Not yet | Dec 20, 2023 | $0target not set | 0 | — | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $21,999,994 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ArkeaBio's Form D filed Oct 9, 2026.
Earlier filings also listed Matthew Dunn (executive officer, last listed Dec 2023), Ginja Silva (executive officer, last listed Dec 2023) and Colin South (president & ceo, director, last listed Dec 2023).